[Estrogen and progesterone receptors in malignant ovarian neoplasms].
Estrogen receptors (ER) and progesterone receptors (PR) were evaluated in 173 primary ovarian cancers and in 6 ovarian metastases. In epithelial ovarian carcinomas 63% had ER and 46% PR. Almost all granulosa cell tumours were receptor-positive, while sarcomas, dysgerminomas, and teratomas lacked ER and PR. Both receptors were found less often in tumours of the histological grade I than in those of grade II and III. During the development of metastases and during chemotherapy there was a loss of PR in 27% and 53% of the cases, respectively, while the amount of ER remained more or less constant. In addition to ovarian cancers ER and PR were present in carcinomas of the fallopian tube as well. ER-negative and especially PR-negative tumours seemed to respond better to chemotherapy than receptor-positive carcinomas. The possible significance of ER and PR with regard to the success of an endocrine treatment is discussed.
D002277:Carcinoma / Q000032:analysis; D004407:Dysgerminoma / Q000032:analysis; D005185:Fallopian Tube Neoplasms / Q000032:analysis; D005260:Female; D006106:Granulosa Cell Tumor / Q000032:analysis; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D010051:Ovarian Neoplasms / Q000032:analysis* / Q000188:drug therapy; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012509:Sarcoma / Q000032:analysis; D013724:Teratoma / Q000032:analysis
D006728:Hormones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Ostrogen- und Progesteronrezeptoren in malignen ovarialtumoren.